18 commercial payer policies list Q2055. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
18 policies from 15 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Chimeric Antigen Receptor T-cell (CAR-T) Therapy: Carvykti and Abecma | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Chimeric Antigen Receptor Therapy (CART): Carvykti & Abecma | Not recorded | Covered with conditionsInferred from policy title |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Chimeric Antigen Receptor T-cell (CAR-T) Therapy: Carvykti and Abecma | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Chimeric Antigen Receptor Therapy (CART): Carvykti & Abecma | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Abecma (idecabtagene vicleucel) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Abecma (idecabtagene vicleucel) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Idecabtagene Vicleucel (e.g., Abecma) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| ABECMA (IDECABTAGENE VICLEUCEL) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Idecabtagene Vicleucel (Abecma) | Jun 30, 2021 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Idecabtagene Vicleucel (Abecma); CP.PHAR.481 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Chimeric Antigen Receptor (CAR) T-cell Therapy | Aug 3, 2026 | Covered |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Abecma | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| UM-MP334 Abecma (idecabtagene vicleucel) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2055 |
|---|---|---|
| Abecma (idecabtagene vicleucel) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |